Holger Dana, Kebriaei Razieh, Morrisette Taylor, Lev Katherine, Alexander Jose, Rybak Michael
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
Department of Microbiology, Virology and Immunology, AdventHealth Central Florida, Orlando, FL 32803, USA.
Antibiotics (Basel). 2021 May 11;10(5):556. doi: 10.3390/antibiotics10050556.
is one of the most common causes of healthcare-associated diseases and is among the top three priority pathogens listed by the World Health Organization (WHO). This Gram-negative pathogen is especially difficult to eradicate because it displays high intrinsic and acquired resistance to many antibiotics. In addition, growing concerns regarding the scarcity of antibiotics against multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections necessitate alternative therapies. Bacteriophages, or phages, are viruses that target and infect bacterial cells, and they represent a promising candidate for combatting MDR infections. The aim of this review was to highlight the clinical pharmacology considerations of phage therapy, such as pharmacokinetics, formulation, and dosing, while addressing several challenges associated with phage therapeutics for MDR infections. Further studies assessing phage pharmacokinetics and pharmacodynamics will help to guide interested clinicians and phage researchers towards greater success with phage therapy for MDR infections.
是医疗保健相关疾病最常见的病因之一，也是世界卫生组织（WHO）列出的三大重点病原体之一。这种革兰氏阴性病原体特别难以根除，因为它对许多抗生素表现出高度的固有耐药性和获得性耐药性。此外，人们越来越担心针对多重耐药（MDR）和广泛耐药（XDR）感染的抗生素短缺，因此需要替代疗法。噬菌体是一种靶向并感染细菌细胞的病毒，是对抗MDR感染的有希望的候选者。本综述的目的是强调噬菌体疗法的临床药理学考虑因素，如药代动力学、制剂和给药剂量，同时解决与MDR感染的噬菌体治疗相关的几个挑战。评估噬菌体药代动力学和药效学的进一步研究将有助于指导感兴趣的临床医生和噬菌体研究人员在MDR感染的噬菌体治疗方面取得更大成功。
